公开(公告)号：US09567339B2

公开(公告)日：2017-02-14

申请号：US14315504

申请日：2014-06-26

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux ,  Heather M. Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep K. Somal ,  Jennifer Van Camp ,  Stacy A. Van Epps ,  Anil Vasudevan ,  Grier A. Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D487/04 ,  C07D417/12 ,  C07D471/04 ,  C07D209/08 ,  C07D417/14 ,  C07D401/14 ,  C07D403/14 ,  C07D231/56 ,  C07D401/12

CPC classification number: C07D209/08 ,  C07D209/10 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：US20200255423A1

公开(公告)日：2020-08-13

申请号：US16654219

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher ,  Theresa A. Dunstan ,  David A. Schiedler

IPC: C07D471/04 ,  C07D487/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US20190276450A1

公开(公告)日：2019-09-12

申请号：US16299485

申请日：2019-03-12

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher

IPC: C07D471/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US10508113B2

公开(公告)日：2019-12-17

申请号：US16299485

申请日：2019-03-12

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher

IPC: C07D405/14 ,  C07D471/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US20170174624A1

公开(公告)日：2017-06-22

申请号：US15398978

申请日：2017-01-05

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux ,  Heather M. Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep K. Somal ,  Jennifer Van Camp ,  Stacy A. Van Epps ,  Anil Vasudevan ,  Grier A. Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D209/08 ,  C07D405/14 ,  C07D403/04 ,  C07D401/04 ,  C07D209/18 ,  C07D405/04 ,  C07D209/12 ,  C07D209/10 ,  C07D209/14 ,  C07D417/14 ,  C07D401/14 ,  C07D409/14 ,  C07D403/10 ,  C07D409/04 ,  C07D409/12 ,  C07D403/14 ,  C07D413/04

CPC classification number: C07D209/08 ,  A61P35/00 ,  C07D209/10 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US20150005279A1

公开(公告)日：2015-01-01

申请号：US14315504

申请日：2014-06-26

Applicant: ABBVIE INC.

Inventor： Dominique Bonafoux ,  Heather M. Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep K. Somal ,  Jennifer Van Camp ,  Stacy A. Van Epps ,  Anil Vasudevan ,  Grier A. Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D487/04 ,  C07D471/04 ,  C07D209/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D231/56 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D209/08 ,  C07D209/10 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。